Drapkin Kimberlee C 4

What Happened
Kimberlee C. Drapkin, a director of LENZ Therapeutics, was granted 22,100 derivative shares on 2026-06-15. The reported acquisition price is $0.00, and the filing classifies the grant as a derivative award rather than a cash purchase or sale.

Key Details

• Transaction date: 2026-06-15; Filing date (Form 4): 2026-06-15 (timely filed).
• Transaction type/code: Grant/Award (A); 22,100 shares acquired at $0.00 (derivative).
• Shares owned after transaction: Not specified in this Form 4.
• Vesting footnote: 100% of the shares vest on the earlier of June 15, 2027 or the date of the next annual meeting, provided Drapkin remains an Outside Director per the company’s policy.
• No indication of a sale, exercise-for-cash, or tax-withholding action in this filing.

Context
This appears to be equity compensation granted to a board member with time-based vesting tied to continued service. Such grants are routine director compensation and do not represent an open-market purchase or sale; they do not, by themselves, indicate immediate trading intent.